Analysts Issue Forecasts for CADL Q4 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Analysts at HC Wainwright issued their Q4 2024 EPS estimates for shares of Candel Therapeutics in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.91) per share.

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $3.99 on Tuesday. The firm’s 50-day simple moving average is $5.96 and its 200 day simple moving average is $6.69. Candel Therapeutics has a 52 week low of $0.77 and a 52 week high of $14.30. The firm has a market capitalization of $129.58 million, a PE ratio of -2.31 and a beta of -0.88. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CADL. State Street Corp grew its holdings in shares of Candel Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after purchasing an additional 19,207 shares during the period. Geode Capital Management LLC boosted its holdings in Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock worth $3,112,000 after acquiring an additional 51,111 shares during the period. Bank of New York Mellon Corp purchased a new position in Candel Therapeutics in the 2nd quarter worth approximately $338,000. Barclays PLC boosted its stake in shares of Candel Therapeutics by 327.1% during the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after buying an additional 21,971 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Candel Therapeutics during the 2nd quarter valued at approximately $162,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Insider Activity at Candel Therapeutics

In related news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the transaction, the insider now owns 929,873 shares of the company’s stock, valued at approximately $5,597,835.46. The trade was a 1.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 31,800 shares of company stock valued at $193,380. 41.60% of the stock is owned by insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.